Initial clinical evaluation of [18F]FSU-880, a PET probe targeting PSMA; safety, distribution, dosimetry and accumulation in prostate cancer.
Not Applicable
- Conditions
- Prostate cancer
- Registration Number
- JPRN-UMIN000029343
- Lead Sponsor
- Department of Diagnostic Radiology Kyoto University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 6
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients having severe communication problem. 2. Patients with severe general condition. 3. Patients having severe renal dysfunction (eGFR<39mL/min/1.73m3) expected to affect the distribution of [18F]FSU-880.. 4. Patients to whom participating physicians judged to be inappropriate for this study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Vital signs and blood and urine analysis data before and after administration of [18F]FSU-880. Dosimetry calculation data based on serial change of [18F]FSU-880 distribution. Qualitative and semi-quantitative uptake of [18F]FSU-880 in known prostate cancer tissue.
- Secondary Outcome Measures
Name Time Method